Experience of a tertiary referral center in managing bladder cancer in conjunction with neurogenic bladder by Sampogna, G. et al.
Spinal Cord Series and Cases            (2020) 6:61 
https://doi.org/10.1038/s41394-020-0302-9
ARTICLE
Experience of a tertiary referral center in managing bladder cancer
in conjunction with neurogenic bladder
Gianluca Sampogna1,2 ● Matteo Maltagliati3 ● Antonio Galfano4 ● Aldo Bocciardi4 ● Bernardo Rocco3 ●
Salvatore Micali3 ● Emanuele Montanari1 ● Michele Spinelli2
Received: 17 February 2020 / Revised: 15 June 2020 / Accepted: 16 June 2020
© The Author(s), under exclusive licence to International Spinal Cord Society 2020
Abstract
Study design Case series.
Objectives The aim of this study was to present our experience with the management of bladder cancer (BCa) in individuals
followed for neurogenic bladder (NB).
Setting An Italian tertiary referral center for NB.
Methods We retrospectively collected all pre-operative, intra-operative, and post-operative data of our NB cases with BCa,
diagnosed from 2004 to 2019.
Results We included ten cases: eight with acquired spinal cord injury (SCI) and two with myelomeningocele (MMC).
Considering individuals with acquired SCI, the median age at BCa diagnosis and time since SCI were 53 and 34 years,
respectively. One out of seven cases had positive urine cytology. All cases underwent a radical cystectomy, diagnosing
squamous cell carcinoma (SCC) and transitional cell carcinoma in 60 and 40% cases, respectively. Surgical-related com-
plications occurred after 90% procedures. Three out of eight individuals with acquired SCI died 2, 12, and 80 months after
the diagnosis. Both individuals with MMC presented no evidence of disease after 24 and 27 months.
Conclusions BCa in individuals with NB proved to be associated with a diagnosis at an advanced stage and a high rate of
surgical complications. In this population we advocate annual genitourinary ultrasound exam and urine cytology, and
cystoscopy in all cases of macrohematuria. Considering the low accuracy of urine cytology and the difficult-to-interpret
inflamed bladder walls at cystoscopy in NB, a patient-tailored follow-up schedule based on specific risk factors (e.g.,
smoking status, indwelling urinary catheter) is mandatory to diagnose and treat BCa at an early stage.
Introduction
Bladder cancer (BCa) is the 5th most commonly diagnosed
cancer in men worldwide, and the 17th most common
cancer in women [1]. Many risk factors for BCa have been
recognized over the years. The most well-established risk
factor is represented by tobacco smoking, which is asso-
ciated with 50–65% of all male cases, and with 20–30% of
females [2]. The second most important risk factor for BCa
is represented by the occupational exposure to aromatic
amines, polycyclic aromatic hydrocarbons, and chlorinated
hydrocarbons, accounting for about 10% of all cases [3].
Other risk factors are bladder schistosomiasis and recurrent
urinary tract infections (rUTIs), which may cause long-
lasting irritation of the bladder epithelium, thus increasing
the BCa risk [4].
Chronic bladder inflammation is common in people with
neurogenic bladder (NB), affected by a variety of diseases
altering the nervous control of the urinary tract, e.g., spinal
cord injury (SCI), myelomeningocele (MM), and multiple
sclerosis [5]. These individuals may perform clean inter-
mittent catheterizations (CICs) or have an indwelling
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urinary catheter (IDC) [6]. The use of an IDC, especially for
more than 10 years, is considered a risk factor for BCa [7].
In addition, individuals with NB often present well-known
bladder irritants, like bladder stones and/or rUTIs [8]. This
population presents unique challenges and a peculiar dis-
ease pattern, characterized by younger age at diagnosis,
high proportion of squamous cell carcinoma (SCC), and
aggressive behavior [9]. Indeed, a meta-analysis by Gui-
Zhong and Li-Bo [10], including 18 studies about BCa in
SCI, outlined a mean age at diagnosis of 50 years, an
estimated percent of SCC of 36.8%, and a 1-year overall
survival rate after treatment of 62.1%.
All these issues highlight the importance of a proper
follow-up strategy for an early diagnosis, even if there is no
current consensus around the world [11].
The aim of this study was to present our experience with
the management of BCa in individuals with NB followed by
a tertiary referral center in order to highlight the peculia-
rities that should be considered for the diagnosis, treatment,
and prognosis of BCa in this population.
Methods
We considered all individuals with SCI who attended our
tertiary referral center for NB-related problems and received
a BCa diagnosis from January 2004 to December 2019. We
retrospectively collected all case details and clinical out-
comes in accordance with our privacy law and with the
Declaration of Helsinki.
The pre-operative data included demographic variables
(e.g., age at BCa diagnosis, sex) and details from medical
history, in particular smoking status, SCI etiology, years
from the index event in case of acquired SCI, previous
genitourinary (GU) surgery, bladder management, and his-
tory of rUTIs.
We screened for events leading to the BCa diagnosis,
histology after transurethral resection of bladder tumor
(TURBT), urinary diversions performed in case of radical
cystectomy (RC), complications associated with RC
(reported according to the Clavien-Dindo classification
system), histology and staging after RC [12].
We assessed the disease status at the last follow-up visit
[13]. In case of death, we investigated the cause of death
and estimated the time lapse from BCa diagnosis to death.
Data were stored anonymously and analyzed using
Microsoft Excel (Microsoft Corporation, Redmond, WA,
USA). We estimated median and interquartile range (IQR)
for each quantitative variable, while we reported the
occurrence of the various outcomes for qualitative variables.
We performed survival analysis with a Kaplan–Meier
model, realized with SPSS, version 20 (IBM Corporation,
Armonk, NY, USA). We did not include individuals with
congenital SCI for descriptive statistics when the early
injury timing might alter some specific variables, like age at
BCa diagnosis and prognosis.
Results
We included ten cases (Table 1), affected by acquired SCI
(n= 8) and congenital MMC (n= 2). Among individuals
with acquired SCI, seven cases had traumatic tetraplegia
(n= 1) and paraplegia (n= 6), while one had transverse
myelitis (n= 1). Eight out of ten individuals were males
(80%), while 2 (20%) cases were females (both with
MMC). In case of acquired SCI, the median age at BCa
diagnosis was 53 years (IQR: 48.75–59; range: 47–83),
while the median time lapse from the index event was 34
years (IQR: 28.5–42.5; range: 22–51). Up to 50% indivi-
duals were smokers at diagnosis.
Five out of ten cases performed CIC (Table 2), while
three cases had an IDC, substituted periodically. Five out of
ten individuals took muscarinic receptor antagonists
(MRA). We identified reflex voiding in two cases.
As for previous GU surgery, 5/10 (50%) individuals
underwent different urethral surgical procedures. Two cases
underwent transurethral cystolithotripsy, while three indi-
viduals received periodical botulinum toxin injections into
the detrusor muscle. Most cases (80%) reported rUTIs.
Macrohematuria was the presenting condition in all
individuals (Table 3). Urine cytology was positive in one
out of seven cases, while negative in 85.7% individuals.
Nine out of ten cases (90%) underwent TURBT with the
following diagnosis: transitional cell carcinoma (TCC) in 6/
9 (66.7%) individuals, with carcinoma in situ in 2/9 cases,
and SCC in the other 3/9 individuals (33.3%).
We addressed 10/10 cases to RC (Fig. 1). We performed
Bricker’s ileal conduits and ureterocutaneostomies in 60
and 30% individuals, respectively. One man underwent an
orthotopic ileal neobladder. After RC, the histology
revealed predominantly a SCC and TCC in 60 and 40%
cases, respectively. Staging was the following: T1 (n= 1),
Tis (n= 1), T2 (n= 5), T3 (n= 1), and T4 (n= 2). No
intra-operative surgical complications occurred. Nine out of
ten (90%) cases reported different-graded post-operative
complications: grade I (n= 2, 20%), grade II (n= 4, 40%),
grade III (n= 3, 30%).
In Table 4, we reported the follow-up of our study
population. In case of acquired SCI, the median overall
survival was 80 months; 3/8 individuals died for cancer-
specific complications 2, 12, and 80 months after the BCa
diagnosis (Fig. 2). Both women with MMC were alive at
the last follow-up visit 24 and 27 months after the BCa
diagnosis. We highlighted no evidence of disease in all 7/10
(70%) living individuals.
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Discussion
The incidence and prevalence of NB are increasing world-
wide [14]. To start with, individuals with SCI are now
living longer with an improved quality of life thanks to
medical advances [15]. Considering long-term complica-
tions, BCa is a life-threating disease which deserves an
early diagnosis and treatment [16]. Indeed, BCa is the third
most frequent cause of death among individuals with
SCI [17].
People with NB may present several added risk factors
for BCa: tobacco smoking, chronic inflammation of the
bladder secondary to the presence of IDCs, bladder stones,
and rUTIs [18]. In our study, rUTIs, smoking, and the use
of IDC were identified in 80, 50, and 30% cases, respec-
tively. Five out of ten individuals had previously undergone
urethral surgery, which may be associated with metaplasia,
thus increasing the risk of BCa, in particular SCC. The
relevance of this correlation has not been fully acknowl-
edged in the literature and further larger, long-term studies
are mandatory to understand the relationship [19]. Chronic
inflammation is usually associated with SCC, which was the
Table 2 Evaluation of bladder
management, previous
genitourinary surgery, and
recurrent urinary tract infections
in the enrolled population.
ID Bladder management History of GU surgeries rUTIs
1 CIC+MRA Urethral bulking BTX injections into the
detrusor wall
No
2 CIC No Yes
3 IDC TUCL Yes
4 IDC+MRA Urethral fistulectomies Yes
5 Reflex voiding No Yes
6 CIC+MRA Endoscopic urethrotomy TUCL No
7 CIC+MRA Urethral fistulectomies BTX injections into the
detrusor wall
Yes
8 Reflex voiding Ureterocelectomy Urethroplasty Yes
9 IDC No Yes
10 CIC+MRA BTX injections into the detrusor wall Yes
Cases: 10 CIC: 5/10 (50%) Urethral surgery: 5/10 (50%) No: 2/10 (20%)
IDC: 3/10 (30%) BTX injections into the detrusor wall: 3/10 (30%) Yes: 8/10 (80%)
MRA: 5/10 (50%) TUCL: 2/10 (20%)
RV: 2/10 (20%) No: 3/10 (30%)
BTX botulinum toxin, CIC clean intermittent catheterization, GU genitourinary, IDC indwelling urinary
catheter, MRA muscarinic receptor antagonist, rUTIs recurrent urinary tract infections, RV reflex voiding,
TUCL transurethral cystolithotripsy.
Table 1 Demographic
characteristics of the enrolled
population.






1 Congenital MMC F 32 – No
2 Congenital MMC F 58 – Yes
3 TM M 83 40 No
4 Traumatic SCI C7 M 71 51 No
5 Traumatic SCI D4 M 48 27 No
6 Traumatic SCI D4-D5 M 53 37 Yes
7 Traumatic SCI D12 M 53 22 Yes
8 Traumatic SCI L1-L2 M 55 50 No
9 Traumatic SCI L1-L2 M 49 31 Yes
10 Traumatic SCI D3 M 47 29 Yes
Cases: 10 MMC: 2/10 (20%) F: 2/10 (20%) Median*: 53 Median: 34 No: 5/10 (50%)
TM: 1/10 (10%) M: 8/10 (80%) IQR*: 48.75–59 IQR: 28.5–42.5 Yes: 5/10 (50%)
Traumatic SCI: 7/10 (70%) Range*: 47–83 Range: 22–51
BCa bladder cancer, F female, IQR inter-quartile range, M male, MMC myelomeningocele, SCI spinal cord
injury, TM transverse myelitis.
*Data estimated considering only individuals with acquired spinal cord injury.
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most common histology in our series (60%), even if other
similar case series reported TCC as the most frequent his-
totype [20, 21]. Besides associated risk factors, current
tendency is to consider NB itself a condition favoring BCa
development [10].
SCI may be associated with a significantly increased
incidence of BCa that has been reported as up to 16–28
times higher compared to the general population [22]. These
individuals present unique challenges. Since they usually
perform CICs or have an IDC, macrohematuria is common,
frequently due to improper maneuvers and/or rUTIs.
Therefore, this issue may divert the attention from the BCa,
especially at an early stage when macrohematuria is often
minimal and sporadic [23]. All our cases were diagnosed
because of long-term macrohematuria, initially
underestimated.
Among symptoms in individuals with SCI, multiple
episodes of autonomic dysreflexia (AD) may be associated
with locally invasive BCa, requiring RC to alleviate
symptoms [24]. A comprehensive diagnostic work-up is
mandatory in individuals with SCI with a lesion above T6,
who present recurrent AD, as it may be the only presenting
symptom of life-threating underlying diseases, like BCa
[25].
Our study highlighted many cases of BCa diagnosed at
an advanced stage, associated with a poor prognosis.
Indeed, most cases (80%) were muscle-invasive forms and
3 out of 10 (30%) individuals died for cancer-specific
complications. This was partially due to a delayed diagnosis
due to an underestimated macrohematuria [26]. Compared
to the general population, the study by Nahm et al. high-
lighted an increased BCa mortality in individuals with SCI
of comparable age, gender, and race, with a standardized
mortality ratio (SMR) of 6.69 with a 95% confidence
interval (CI) of 5.44–8.14 [27]. In particular, a time lapse
greater than 20 years after SCI was associated with a sig-
nificantly increased SMR: 17.83 (95% CI: 14.00–22.39).
The role of urine cytology in the early diagnosis of BCa
in individuals with NB is a debated issue. In our series, one
out of seven cases had positive urine cytology. Since the
urine cytology has low accuracy in SCC diagnosis and the
incidence of SCC seems to be higher in this population,
urine cytology may have a reduced role during the follow-
up of people with NB [28]. A systematic review published
in 2018 concluded urinary cytology outperformed cysto-
scopy for BCa screening: sensitivity and specificity for
Fig. 1 Surgical specimen of case n°10. The patient underwent a
laparoscopic radical cystectomy and perineal urethrectomy, then an
intracorporeal Bricker’s ileal conduit urinary diversion was realized.
Surgical pathology revealed pTis, pNx.
Table 4 Follow-up of the considered population.
ID Months from BCa diagnosis to last
















BCa bladder cancer, CSD cancer-specific death, NED no evidence of
disease.
*Data estimated considering only individuals with acquired spinal cord
injury.
Fig. 2 Survival curve in case of acquired spinal cord injury.
Kaplan–Meier plot displaying the survival of eight cases after the
bladder cancer diagnosis. Three individuals died after 2, 12, and
80 months.
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urine cytology vs. cystoscopy were, respectively, 0–72%
and 100% vs. 27–81% and 54% [29].
Inflamed and diverticular walls in NB may be difficult to
interpret, undermining diagnostic accuracy, and inducing a
high-rate of false positives: these limits may be overcome
by novel promising imaging technologies, like photo-
dynamic diagnosis and narrow-band imaging, even if their
role has to be still investigated thoroughly in the NB
population [30, 31].
Surveillance patterns vary around the world, as there is
no consensus among authors and organizations [32]. At
our center, we assess our NB cases annually, updating
medical history, performing clinical examination, and
viewing bladder diary and reports of renal laboratory tests,
urinalysis, urine cytology, and imaging surveillance of the
urinary tract, usually via GU ultrasound exam [33]. Further
study may be required in case of suspicious signs and/or
symptoms (i.e., macrohematuria), changes in bladder
behavior (i.e., increased urine leaks), or presence of risk
factors (i.e., tobacco use) [34]. In these cases, follow-up
plans should be modified with more frequent checkups
and/or additional diagnostic exams, like cystoscopy,
videourodynamics, abdominal computed tomography
scan, and renal scintigraphy.
Until more accurate diagnostic strategies are available,
we advocate at least annual urine cytology and GU ultra-
sound exam in asymptomatic cases. The timing of follow-
up may be shortened in case of specific risk factors (e.g.,
IDC, smoking habit, and occupational exposure) [35].
Considering the high rate of false negatives with urine
cytology, bladder cystoscopy with biopsies of the suspi-
cious areas is required in all cases of macrohematuria [36].
We considered individuals with congenital MMC as a
different subset for descriptive statistics of baseline char-
acteristics and follow-up, as the associated injury provoked
NB from fetal life and might induce BCa in a younger stage
of life. Indeed, the youngest case at diagnosis (32 years) was
affected by MMC. Previous studies identified 15–20 years
since the index event as a warning to investigate BCa in
individuals with acquired SCI. Therefore, clinicians should
exclude BCa in all young adults with MMC presenting with
macrohematuria, as they developed a NB during fetal life.
The urinary diversion choice in this population should
consider manual dexterity, individual preferences, care-
giver support, disease stage and residual renal function
[37]. Only one case underwent an orthotopic ileal neo-
bladder because of the disease characteristics (tumor dis-
tant from the bladder neck), individual’s conditions (valid
performance status, young age) and surgeon’s preferences
[38]. In addition, this man did not void by the Valsalva
maneuver, but continued CICs.
We registered a very high rate of surgical complications
(90%) [39]. This was due to the limited functional reserve to
cope with surgical stress [40]. The current treatment guide-
lines for BCa have been developed for the general population
without considering the challenges and needs of this popu-
lation. Some precautions may be adopted in the future to
reduce surgical morbidity. Post-operative anemia may be
limited by a pre-operative iron deficiency detection and
eventually through intravenous iron formulations [41].
Antibiotic therapy may be started 48 h before surgery to limit
post-operative infections and febrile episodes. Paralytic ileus
in neurogenic bowel may be reduced with adequate bowel
preparation, pharmacotherapy with pyridostigmine or alvi-
mopan, and adherence to the recommendations from the
Enhanced Recovery After Surgery Society [42]. Future ran-
domized controlled trials may evaluate outcome improve-
ments with these proposed solutions.
Considering the high rate of complications following
open major surgery, an early diagnosis of BCa is essential
to perform a radical TURBT and reduce the morbidity in
this population.
Our study presents several limits. It has a retrospective
design; the level of evidence is four according to the Oxford
Center for Evidence-based Medicine [43]. The follow-up is
short for some cases. The sample is relatively small, even if
it includes all individuals with NB followed by our center,
so it is representative of the incidence and prevalence of
BCa in people treated by a tertiary referral center for NB.
We have noticed an increased incidence of BCa in the
considered population over the last years, probably due to
the extended life expectancy of the individuals with SCI.
As for future directions, our study represents a con-
tribution to outline the peculiar BCa disease pattern and the
patient-specific conditions for a proper follow-up of people
with NB, also by presenting data for further systematic
reviews and meta-analyses [44]. Since the prevalence and
incidence of individuals with SCI are increasing worldwide,
appropriate indications in terms of follow-up to diagnose
and treat BCa at an early stage should be a priority of
scientific societies and organizations involved in the man-
agement of this population [45].
Conclusions
We reported the experience of a tertiary referral center in the
management of BCa in individuals followed for NB. BCa in
this population proved to be particularly aggressive, usually
diagnosed as SCC at an advanced stage, and associated with
a high rate of post-operative complications and mortality.
Considering the limits of current diagnostic strategies, like
urine cytology and cystoscopy, further multi-center studies
focusing on long-term management and carcinogenesis in
NB are mandatory to define a proper follow-up schedule to
diagnose BCa at an early stage and improve the prognosis
and quality of life of these individuals. Until then, we
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advocate a life-long follow-up strategy based on at least
annual GU ultrasound exam and urine cytology, a patient-
tailored approach considering specific risk factors (e.g.,
smoking habit, long-term IDC), and prompt cystoscopy in
all cases of macrohematuria.
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